Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
University of Southern California
mi
from
Los Angeles, CA
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
University of Colorado
mi
from
Denver, CO
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Emory University
mi
from
Atlanta, GA
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
University of Iowa
mi
from
Iowa City, IA
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
University of South Carolina
mi
from
Columbia, SC
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
University of South Carolina
mi
from
Columbia, SC
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
The University Of Texas
mi
from
Houston, TX
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
The University Of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated:  2/6/2017
Univ of Puerto Rico
mi
from
San Juan,
Vitamin D/Calcium Polyp Prevention Study
Vitamin D/Calcium Polyp Prevention Study
Status: Enrolling
Updated: 2/6/2017
Univ of Puerto Rico
mi
from
San Juan,
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Children's Hospital at Montefiore
mi
from
Bronx, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Maimonides Medical Center
mi
from
Brooklyn, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Maimonides Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
NYU Langone Medical Center
mi
from
New York, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated:  2/7/2017
Mount Sinai Hospital
mi
from
New York, NY
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
Status: Enrolling
Updated: 2/7/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Hackensack, NJ
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Durham, NC
AMG 319 Lymphoid Malignancy FIH
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Phase I Study of CS-7017 and Bexarotene
A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene
Status: Enrolling
Updated:  2/13/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Phase I Study of CS-7017 and Bexarotene
A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene
Status: Enrolling
Updated: 2/13/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  2/13/2017
Washington University School of Medicine Dept of Oncology.
mi
from
St. Louis, MO
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 2/13/2017
Washington University School of Medicine Dept of Oncology.
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  2/13/2017
Sarah Cannon Research Institute Dept of Onc
mi
from
Nashville, TN
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 2/13/2017
Sarah Cannon Research Institute Dept of Onc
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  2/13/2017
Memorial Sloan Kettering Cancer Center Onc. Dept
mi
from
NY, NY
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 2/13/2017
Memorial Sloan Kettering Cancer Center Onc. Dept
mi
from
NY, NY
Click here to add this to my saved trials
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  2/13/2017
Novartis Investigative Site
mi
from
Rouen Cedex 1,
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 2/13/2017
Novartis Investigative Site
mi
from
Rouen Cedex 1,
Click here to add this to my saved trials
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  2/13/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 2/13/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated:  2/14/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant
Status: Enrolling
Updated: 2/14/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  2/15/2017
Seby B. Jones Cancer Center
mi
from
Boone, NC
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 2/15/2017
Seby B. Jones Cancer Center
mi
from
Boone, NC
Click here to add this to my saved trials
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  2/15/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 2/15/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  2/15/2017
Northeast Medical Center
mi
from
Concord, NC
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 2/15/2017
Northeast Medical Center
mi
from
Concord, NC
Click here to add this to my saved trials
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  2/15/2017
Moses Cone Regional Cancer Center
mi
from
Greensboro, NC
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 2/15/2017
Moses Cone Regional Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  2/15/2017
Leo Jenkins Cancer Center, East Carolina University Medical Center
mi
from
Greenville, NC
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 2/15/2017
Leo Jenkins Cancer Center, East Carolina University Medical Center
mi
from
Greenville, NC
Click here to add this to my saved trials
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  2/15/2017
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 2/15/2017
Marion L. Shepard Cancer Center
mi
from
Washington, NC
Click here to add this to my saved trials
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  2/15/2017
Rex Healthcare
mi
from
Raleigh, NC
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 2/15/2017
Rex Healthcare
mi
from
Raleigh, NC
Click here to add this to my saved trials
Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials
Procurement of Follicular B Cell Lymphoma Cells From Blood, Tissue or Malignant Effusion for the Purpose of Possible Use in Future Clinical Trials: A Minimal Risk Protocol
Status: Enrolling
Updated:  3/8/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials
Procurement of Follicular B Cell Lymphoma Cells From Blood, Tissue or Malignant Effusion for the Purpose of Possible Use in Future Clinical Trials: A Minimal Risk Protocol
Status: Enrolling
Updated: 3/8/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated:  3/15/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated: 3/15/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated:  3/15/2017
Rush University Medical Center
mi
from
Chicago, IL
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated: 3/15/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated:  3/15/2017
Washington University
mi
from
St. Louis, MO
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated: 3/15/2017
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated:  3/15/2017
John H. Stroger Cook County Hospital
mi
from
Chicago, IL
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated: 3/15/2017
John H. Stroger Cook County Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated:  3/15/2017
Loyola University Medical Center
mi
from
Maywood, IL
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated: 3/15/2017
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated:  3/15/2017
Advocate Lutheran General Cancer Care Center
mi
from
Park Ridge, IL
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated: 3/15/2017
Advocate Lutheran General Cancer Care Center
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated:  3/15/2017
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated: 3/15/2017
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated:  3/15/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma
Status: Enrolling
Updated: 3/15/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL
An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated:  3/16/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL
An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated: 3/16/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL
An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated:  3/16/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL
An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated: 3/16/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL
An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated:  3/16/2017
City of Hope
mi
from
Duarte, CA
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL
An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Status: Enrolling
Updated: 3/16/2017
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)
Status: Enrolling
Updated:  3/20/2017
Ohio State University Medical Center
mi
from
Columbus, OH
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)
Status: Enrolling
Updated: 3/20/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
Status: Enrolling
Updated:  3/21/2017
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
Status: Enrolling
Updated: 3/21/2017
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
Status: Enrolling
Updated:  3/21/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
Status: Enrolling
Updated: 3/21/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
LS1081, "A Pilot Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation or Intradermally for Patients With B-Cell Non-Hodgkin's Lymphoma"
Status: Enrolling
Updated:  3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
LS1081, "A Pilot Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation or Intradermally for Patients With B-Cell Non-Hodgkin's Lymphoma"
Status: Enrolling
Updated: 3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials